Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 7/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6585284 | 0.98 | DPP4 (0.53) | HSD11B1DPP4LMNASLC6A4L3MBTL1 | |
| SCHEMBL6554492 | 0.95 | LMNA (0.49) | HSD11B1DPP4LMNASLC6A4L3MBTL1 | |
| SCHEMBL6583082 | 0.91 | MAOA (0.50) | HSD11B1DPP4LMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL5365797 | 0.85 | HSD11B1 (0.72) | HSD11B1DPP4LMNASLC6A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11526870 | 0.84 | HSD11B1 (0.70) | HSD11B1DPP4LMNASLC6A4L3MBTL1 | |
| SCHEMBL977926 | 0.83 | HSD11B1 (0.69) | HSD11B1DPP4LMNASLC6A4L3MBTL1 | |
| SCHEMBL1334115 | 0.83 | HSD11B1 (0.51) | HSD11B1DPP4LMNASLC6A4L3MBTL1 | |
| SCHEMBL11611383 | 0.82 | SLC6A4 (0.54) | HSD11B1DPP4LMNASLC6A4L3MBTL1 | |
| SCHEMBL17761202 | 0.82 | DPP4 (0.56) | HSD11B1DPP4LMNASLC6A4L3MBTL1 | |
| SCHEMBL2644998 | 0.80 | DPP4 (0.53) | HSD11B1DPP4LMNASLC6A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0986545-B1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| US-20030203902-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| US-6548534-B2 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-15 | — | — | US | disclosed |
| US-20020016365-A1 | Nonsteroidal gestagens | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| US-6344454-B1 | CONTRACEPTIVE PREPARATIONS,TREATMENT OF ENDOMETRIOSIS, GYNECOLOGICAL DISORDERS,PREMENSTRUAL SYMPTOMS, MALE BIRTH CONTROL, MALE HRT AND HORMONE THERAPY AND FOR TREATING ANDROLOGICAL DISEASE AGENTS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-05 | — | — | US | disclosed |
| US-6245804-B1 | CONTRACEPTIVES; UROGENITAL DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| EP-0986545-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054159-A1 | NON-STEROIDAL (HETERO) CYCLICALLY SUBSTITUTED ACYLANILIDES WITH MIXED GESTAGEN AND ANDROGEN ACTIVITY | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016365-A1 | Nonsteroidal gestagens | NR5A1, GPER1, ESR2 | HSD11B1 175/4885DPP4 4730/4885LMNA 1909/4885 |
| US-20030203902-A1 | Nonsteroidal gestagens | GPER1, NR5A1, ESR2 | HSD11B1 189/4885DPP4 4708/4885LMNA 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.